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Background: The safety of pharmacotherapy in atrial 
fibrillation (AF) is compounded by a trilogy of risks old age, 
high-risk medications (e.g., antithrombotics, 
antiarrhythmics), polypharmacy due to multiple patient 
comorbidities. However, to date, scarce study has 
investigated the use of polypharmacy (including potentially 
inappropriate medication (PIM)) in AF patients, and how 
this may contribute to their overall risk of medication 
misadventure. 
Objectives: To review the extent of polypharmacy and 
PIM use in older patients (65 years or older) with AF. 
Methods: Information was extracted from a database 
characterising a cohort of older AF patients treated in 
general practice in New South Wales, Australia. Patient 
characteristics, number and types of drugs, the degree of 
PIM use were recorded. The predictors for the use of 
polypharmacy in older AF patients were identified.  
Results: Overall, 367 patients (mean age 77.8 years) 
were reviewed, among which 94.8% used 5 medications 
or more and over half used 10 medications or more. 
Cardiovascular agents were most commonly used 
(98.9%), followed by antithrombotics (90.7%). Among 
agents deemed PIMs, digoxin (30.2%) was the most 
frequently used, followed by benzodiazepines (19.6%), 
and sotalol (9.8%). AF patients using polypharmacy were 
more likely to have low bleeding risk (OR=10.97), 
representing those patients in whom high-risk 
antithrombotics are mostly indicated. Patients with major-
polypharmacy (5-9 medications) are more likely to have 
obstructive pulmonary diseases (OR=2.32), upper 
gastrointestinal diseases (OR=2.02) and poor physical 
function (OR=1.04), but less likely to have cognitive 
impairment (OR=0.27). 
Conclusion: Polypharmacy affects oldest AF patients, 
comprising medications that are indicated for AF, yet 
regarded as PIMs. Patients with lower risk of bleeding, 
obstructive pulmonary diseases, upper gastrointestinal 
diseases and poor physical function are also at higher risk 
of using higher number of medications. This may lead to 
an increased risk for medication misadventure due to the 
concomitant use of polypharmacy and medications for AF.  
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INTRODUCTION 
Atrial fibrillation (AF) is a leading cause of morbidity 
and mortality. It is associated with a significantly 
increased risk of stroke, heart failure and dementia.
1
 
In regard to its management, the American College 
of Cardiology/American Heart Association and 
European Society of Cardiology guidelines 
recommend the use of both antiarrhythmics and 
antithrombotics.
1,2
 Similar recommendations are 
presented within Australian guidelines.
3
 However, 
despite guidelines, patients with AF present a 
quandary for health care professionals. First, their 
age (i.e., being older persons) presents specific 
challenges in the selection of medicines and 
associated management, due to age-related 
physiological changes as well as functional and 
cognitive impairments.
4
 Second, the need to use 
high-risk medications (e.g., antithrombotics and 
antiarrhythmics), as indicated by clinical guidelines, 




However, the risks do not stop here. In fact, patients 
with AF are exposed to a trilogy of risks, inherent to 
their overall disease presentation and management. 
Aside from their advancing age and the use of high-
risk medicines, there is an additional risk factor: 
polypharmacy. A multitude of agents may be 
prescribed to AF patients for stroke prevention, 
management of the arrhythmia, treatment of 
accompanying cardiovascular and stroke risk 
factors, as well as therapies for other comorbidities. 
Collectively, these complicate medication 
management and increase the risk of medication 
misadventure, manifesting as non-adherence, 
adverse drug reactions (ADRs), and drug 
interactions, all of which can lead to poor clinical 
outcomes.
5
 In turn, this complicates health 
professionals’ decision-making, particularly in 




International studies have shown that polypharmacy 
is common in patients with AF
7,8
 and in patients 
using anticoagulants.
3
 However, in Australia, little 
attention has been paid to the degree of 
polypharmacy in elderly AF patients and how this 
may contribute to their overall risk of medication 
misadventure. Therefore, the aim of this study was 
to characterise AF patients in the Australian primary 
care setting in terms of this ‘trilogy’ of risks, and to 
specifically: 1) describe the extent of use of 
polypharmacy in older AF patients; 2) determine the 
degree to which these medications may be 
potentially inappropriate; 3) identify factors 
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associated with the use of polypharmacy; and 4) 
identify factors associated with major polypharmacy 
versus minor polypharmacy in older AF patients. 
 
METHODS  
Ethical approval  
Ethics approval was obtained from the participating 
institutions.
9
 Patient data were coded and de-
identified prior to analysis. 
Design  
In this cross-sectional study, information was 
extracted from a database pertaining to a cohort of 
AF patients (65 years or older) recruited for a 
previous study conducted in general practices within 
metropolitan and regional areas of New South 
Wales, Australia (detailed description of the study 
recruitment/data collection methods is reported 
elsewhere).
9
 Patients with a confirmed diagnosis of 
AF were recruited by their general practitioners 
(GPs) during routine care.  
Data Collection 
Purpose-designed data collection instruments were 
used to extract and record data from medical notes, 
patient interviews, and a brief patient survey (e.g., 
medical history, medication use). All collected data 
were verified by the patients’ GPs.  
Definitions and Measures 
Polypharmacy is most commonly defined as the use 
of five or more regular medications.
10
 For the 




• Non-Polypharmacy: four or less medications  
• Minor-Polypharmacy: use of five to nine 
medications  
• Major-Polypharmacy: concomitant use of ten or 
more medications  
Diagnoses were coded using the World Health 
Organization (WHO) International Statistical 









 scores 0, 1, 2 or 
over were classified as low, intermediate and high 
stroke risk, respectively. HAS-BLED
15
 scores 0, 1-2, 
3 or over were classified as low, intermediate and 
high bleeding risk, respectively. 
HEMORR2HAGES
16
 scores 0-1, 2-3, 4 or over were 
classified as low, intermediate and high bleeding 
risk, respectively. In this study, CHA2DS2VASc and 
HAS-BLED were used as they are commonly 
recommended by international guidelines.
14,15
 
Although CHA2DS2VASc and HAS-BLED are 
advocated in more recent European Society of 
Cardiology guidelines, CHADS2 was additionally 
used in this study because it is included in 
Australian local guidelines (e.g., National 





), while HEMORR2HAGES was 
used because it is recommended by National 
Clinical Guideline Centre (UK) and American 
College of Cardiology/American Heart Association 
guidelines.
16,19
 Moreover, since these scoring tools 
have different sensitivities and specificities, the use 
of four scores assisted in reducing any false 
positives and false negatives in the risk 
assessment. SF-36, a survey, which provides 
psychometrically-based physical and mental health 
summary measures and a preference-based health 
utility index, was also used.
20
 
Recorded medications included both over-the-
counter and prescription medicines used by patients 
(as documented in their medication histories), 
regardless of short-term or long-term use. All 
medications were classified according to Anatomical 
Therapeutic Chemical (ATC) classification system.
21
 
The medications used by patients were then 
assessed to whether they were ‘potentially 
inappropriate medicines’ (PIMs) for older patients, 
according to two explicit criteria, i.e. Beers criteria 
2012
22
 and PRISCUS criteria.
23
 Both Beers criteria 
and PRISCUS criteria were selected because of 
slight variations in defining certain medications as 
potentially inappropriate based on the dosage (e.g., 
digoxin).  
Statistical Analysis 
Computerised data analysis employed SPSS 
(Statistical Package for the Social Sciences 
Version.
19
 To explore relationships involving 
continuous variables, ANOVA (parametric 
distribution) and Kruskal-Wallis (non-parametric 
distribution) were used. The Chi-square test 
examined differences in independent proportions. 
Multivariate logistic regression (Forward Wald) 
analysis was used to assess the influence of the 
predictors on polypharmacy. p<0.1 was used in 
multivariate logistic regression. p<0.05 was 





The mean age of patients (N=367) was 77.8 years; 
two-thirds were less than 75 years old. The age 
categories were based on those used by clinical 
guidelines for anticoagulant treatment, as well as 
the apparent distribution of polypharmacy by age in 
the cohort (Table 1). In terms of their AF history, 
most (87.5%) patients had AF for at least 1 year, 
with over half (57.5%) diagnosed as having 
persistent AF. Most patients were categorised as 
being at least at intermediate risk of stroke (92.1% 
by CHADS2 and 100% by CHA2DS2VASc). Over 
half of the patients (53.4%) were identified to have 
‘intermediate’ or ‘high’ bleeding risk as per 
HEMORR2HAGS and 93.9% patients were 
identified to have ‘intermediate’ or ‘high’ as per 
HAS-BLED scores.  
Extent of polypharmacy  
Overall, 348 (94.9%) patients were using some 
degree of polypharmacy, whilst just over half 
(55.9%; n=205) of the patients were using major-
polypharmacy (Table 1). Compared to patients in 
the non-polypharmacy group (5.1% of patients), 
those with minor-polypharmacy and major-
polypharmacy had more comorbidities (p<0.01) 
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(Table 2). In terms of major diseases (excluding 
AF), patients in the major-polypharmacy group had 
a higher incidence of diabetes (p<0.01), upper 
gastrointestinal (GI) discomfort (p<0.01), and 
asthma or chronic obstructive pulmonary disease 
(p<0.01). Patients in the major-polypharmacy group 
had a significantly lower SF-36 physical score than 
those with minor-polypharmacy or non-
polypharmacy (p=0.01).  
Polypharmacy in AF patients according to ‘risk 
category’ 
When comparing the use of polypharmacy by stroke 
risk (per CHADS2), a higher proportion of patients 
used polypharmacy among those at high risk of 
stroke, compared to those at low risk of stroke 
(98.4% vs. 84.6%, p=0.002). When compared by 
bleeding risk (per HEMORR2HAGS), a higher 
proportion of patients used polypharmacy among 
those at intermediate risk of bleeding, compared to 
those at high risk of bleeding (96.5% vs. 86.2%, 
p=0.013) (Table 1). When comparing the use of 
polypharmacy across various risk categories per 
CHA2DS2VASc and HAS-BLED scores, no 
significant difference was found. 
A number of patients were identified as having 
specific medication safety issues that might affect a 
patient’s medication management ability and/or put 
them at a risk of medication misadventure. Among 
those patients with documented cognitive 
impairment (n=18), 83.3% had major-polypharmacy 
and the remainder had minor-polypharmacy. Among 
all of the patients who reportedly needed assistance 
with medication management, 46.3% had major-
polypharmacy and the remainder had minor-
polypharmacy. All patients with poor medication 
adherence (self-reported) had some degree of 
polypharmacy; almost three quarters (72.7%) of 
these patients had major-polypharmacy (Table 2). 
Number and types of drugs 
Patients with major-polypharmacy used almost two 
and half times the mean number of medications 
(mean=2.5, SD=1.0) per diagnosed disease, 
compared to non-polypharmacy patients 
(mean=1.1, SD=0.5, P<0.01). Unsurprisingly, drugs 
Table 1. Patient characteristics 
Characteristics 



















Gender      0.07 
male 13 (3.5) 87 (23.7) 103 (28.1)  
             female 6 (1.6) 56 (15.3) 102 (27.8)  
Age  μ (SD) 75.5 (6.8) 77.5 (6.9) 78.2 (7.1) 0.17 
Age group    0.38 
 ≥75 years 9 (2.4) 91 (24.8) 129 (24.6)  
<75 years 10 (2.7) 52 (14.2) 76 (20.7)  
Type of AF    0.56 
†
 
Paroxysmal 5 (1.4) 49 (13.3) 73 (19.9)  
Persistent 12 (3.3) 86 (23.4) 113 (30.8)  
New Onset 1 (0.3) 6 (1.6) 14 (3.8)  
Unknown 1 (0.3) 2 (0.6) 5 (1.4)  
History of AF    0.78 
<1 year 3 (0.8) 16 (4.4) 27 (7.4)  
≥ 1 year 16 (4.4) 127 (34.6) 178 (48.5)  
Current Cardiac Rhythm    0.22
‡
 
Normal Sinus Rhythm 2 (0.8) 11 (3.0) 28 (7.6)  
Controlled AF   17 (4.6) 131 (8.4) 177 (48.2)  
Uncontrolled AF 0 (0.0) 1 (0.3) 0 (0.0)  
CHADS2 score
§
     
Low 4 (1.2) 11 (3.0) 14 (3.8) 0.004 
Intermediate 7 (1.9) 53 (14.4) 48 (13.1)  
High 8 (2.4) 77 (20.9) 143 (38.9)  
CHA2DS2-VASc score
§
     
Intermediate 2 (0.6) 6 (1.6) 6 (1.6) 0.24 
High 17 (4.6) 137 (37.3) 199 (54.2)  
HEMORR2HAGS score
¶
     
Low 14 (3.8) 75 (20.4) 81 (22.1) 0.04 
Intermediate 3 (0.8) 65 (17.7) 116 (31.6)  
High 2 (0.6) 3 (0.8) 8 (2.4)  
HAS-BLED  score
#
     
Low 1 (0.3) 2 (0.6) 2 (0.6) 0.51 
Intermediate 15 (4.1) 124 (33.8) 177 (48.2)  
High 3 (0.8) 17 (4.6) 26 (7.1)  
* Difference among non-polypharmacy, minor-polypharmacy and major-polypharmacy 
† P value: persistent compared with all other 
‡ P value: sinus rhythm compared with all other 
§ CHADS2 (13) and CHA2DS2VASc (14)  scores of 0, 1, ≥ 2 were classified as low, intermediate and high stroke risk, 
respectively. 
¶  HEMORR2HAGES (16) scores of 0-1, 2-3, ≥ 4 were classified as low, intermediate and high bleeding risk, 
respectively.  
#  HAS-BLED (15) scores of 0, 1-2, ≥ 3 were classified as low, intermediate and high bleeding risk, respectively.  
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acting on the cardiovascular system, as well as 
blood and blood forming agents, were the most 
commonly used medications (Table 3 and 4). Since 
all patients had at least an intermediate stroke risk 
(as per CHA2DS2VASc), most were taking 
warfarin±aspirin (79.8%) and around one in ten 
were on dabigatran (11.7%). Around one in twenty 
patients were using aspirin or clopidogrel (6.8%) 
(Table 5). Among all patients, nearly two-thirds were 
using beta blockers (59.4%), while around one in 
ten patients were using sotalol (9.8%) or 
nondihydropyridine calcium channel blockers 
(10.3%). Surprisingly, 30.2% patients were using 
digitalis glycosides (digoxin), despite it not being 
indicated as a first-line therapy by clinical guidelines 
(24) and noting that it is identified as a PIM. Among 
“non-cardiovascular” medications, analgesics (N02) 
and drugs for acid-related disorders were most 
commonly used (taken by over half of the patients). 
Among these, 55.3% of patients were using 
analgesics in combination with antithrombotics, 
comprising 137 (37.3%) patients using warfarin 
concurrently with paracetamol, 32 (8.7%) patients 
using warfarin concurrently with opioids, and 9 
(2.5%) patients using warfarin concurrently with 
nonsteroidal anti-inflammatory drugs (NSAIDs).  
Factors associated with polypharmacy versus 
non-polypharmacy 
Univariate analysis was used to identify the factors 
associated with polypharmacy (5 medications or 
more) versus non-polypharmacy. Univariate 
analysis identified that patients using polypharmacy 
were more likely to have a higher stroke risk, per 
CHADS2 (OR=4.40, 95%CI 1.23-15.66, p=0.03 
compared with low stroke risk) and a lower bleeding 
risk, per HEMORR2HAGS (OR=10.97, 95%CI 1.66-
72.60, p=0.01 compared with high bleeding risk). In 
multivariate analysis, only a lower bleeding risk 
(HEMORR2HAGS) remained a significant predictor 
of polypharmacy (OR=10.97, 95%CI 1.66-72.60, 





=0.09, 94.8% correctly predicted). 
CHA2DS2VASc and HAS-BLED were not found to 
be significantly associated with polypharmacy. 
Univariate analysis was used to identify the factors 
associated with major-polypharmacy versus minor-
polypharmacy. Univariate analysis identified that 
patients using major-polypharmacy were more likely 
to have higher number of comorbidities (OR=1.28, 
95%CI 1.15-1.42, p<0.001), upper gastrointestinal 
disease (includes gastric ulcer, gastritis, 
oesophagitis/ulcer, duodenal ulcer or 
Table 2. Medication safety considerations 
Characteristics 



















Comorbidities. μ (SD) 4.7 (3.3) 5.0 (2.4) 6.3 (2.4) <0.01 
Number of drugs (both prescription and 
non-prescription).  μ (SD) 
3.9 (0.6) 7.4 (1.4) 13.9 (3.4) <0.01 
Prescription drugs  μ (SD) 3.47 (0.6) 6.3 (1.5) 12.0 (3.3) <0.01 
Non-prescription drugs (e.g., OTC, 
supplements). μ (SD) 
0.21 (0.4) 1.08 (1.0) 1.9 (1.4) <0.01 
Cognitive impairment 0 (0.0) 3 (0.8) 15 (4.1) 0.07 
Visual impairment 0 (0.0) 8 (2.2) 14 (3.8) 0.70 
Hearing impairment 2 (0.6) 9 (7.9) 20 (6.2) 0.48 
Language barrier 0 (0.0) 1 (0.3) 3 (0.8) 0.71 
Mobility impairment 1 (0.3) 4 (1.1) 12 (3.3) 0.34 
Residential care facility 0 (0.0) 1 (0.3) 3 (0.8) 0.71 
Difficulty access medical care 0 (0.0) 2 (0.6) 1 (0.3) 0.63 
Need assistance with medication 4 (1.1) 51 (13.9) 95 (25.9) 0.03 
Poor adherence (self-reported) 0 (0.0) 6 (1.6) 16 (4.4) 0.27 
Other major diseases      
Chronic heart failure 3 (0.8) 38 (10.3) 51 (13.9) 0.65 
Hypertension 12 (3.7) 97 (26.4) 140 (38.1) 0.88 
Diabetes 1 (0.3) 37 (10.1) 35 (9.5) 0.03 
Prior stroke or TIA 5 (7.5) 27 (7.3) 35 (9.5) 0.52 
Coronary heart disease 3 (0.8) 43 (11.7) 64 (16.9) 0.40 
Asthma or COPD 4 (1.1) 12 (3.7) 43 (11.7) <0.01 
Arthritis (OA, RA, Psoriasis Arthritis) 3 (0.8) 32 (8.7) 62 (16.9) 0.16 
Upper GI discomfort 
 †
 3 (0.8) 33 (8.9) 88 (24.0) <0.01 
Renal disease 0 (0.0) 7 (1.9) 9 (2.3) 0.92 
Previous fall 0 (0.0) 4 (1.2) 7 (1.2) 1.00 
Self-reported Health SF-36
 ‡
     
Physical. μ (SD) 46.5 (5.9) 45.1 (8.2) 42.4 (7.4) <0.01 
Mental.  μ (SD) 58.2 (3.8) 55.4 (7.1) 54.8 (7.4) 0.10 
TIA =transient ischaemic attack, COPD =chronic obstructive pulmonary disease, OA =osteoarthritis, RA= rheumatoid 
arthritis, GI= gastrointestinal, SF-36 =The Short Form (36) Health Survey is a patient-reported survey of patient health. 
* Difference between non-polypharmacy, minor-polypharmacy and major-polypharmacy 
† Upper GI diseases include gastric ulcer, gastritis, esophagitis/ulcer, duodenal ulcer or gastroesophageal reflux disease 
‡ SF-36, a survey, which provides psychometrically-based physical and mental health summary measures and a 
preference-based health utility index (54). A high score of SF-36 means better health. Physical includes: Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning. Mental includes: Role-Emotional, 
Mental Health 
Wang Y, Singh S, Bajorek B. Old age, high risk medication, polypharmacy: a trilogy of risks in older patients with atrial 
fibrillation. Pharmacy Practice 2016 Jan-Mar;14(2):706.  
doi: 10.18549/PharmPract.2016.02.706 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 5 
gastroesophageal reflux disease, OR=2.51, 95%CI 
1.56-4.04, p<0.001), obstructive pulmonary disease 
(asthma or chronic obstructive pulmonary disease 
(COPD), OR=2.89, 95%CI 1.47-5.72, p=0.002), and 
poor physical function (as measured by SF-36 
physical score, OR=1.05, 95%CI 1.02-1.08, 
p=0.003), but less likely to have cognitive 
impairment (OR=0.27, 95%CI 0.07-0.96, p=0.04). In 
multivariate analysis, obstructive pulmonary disease 
(adjusted OR=2.32, 95%CI 1.14-4.71, p=0.02), 
upper gastrointestinal disease (adjusted OR=2.02, 
95%CI 1.23-3.34, p=0.006), cognitive impairment 
(adjusted OR=0.27, 95%CI 0.07-0.97, p=0.04), and 
poor physical function (as measured by SF-36 
physical score, adjusted OR=1.04, 95%CI 1.00-
1.07, p=0.01) remained significant predictors of 





=0.13, 63.5% correctly predicted). 
Inappropriate use of medications 
Overall, 250 (68%) patients (mean age 77.9 years) 
were using at least 1 PIM (Table 3 and 4). Among 
the most frequently identified PIMs (Table 4), four 
agents were for rhythm and/or rate control: digoxin 
(30.2%), sotalol (9.8%), amiodarone (7.9%), and 
flecainide (2.2%). Among those on digoxin, only 24 
(21.6%) patients had a documented diagnosis of 
chronic heart failure, as required by guidelines (24). 
The most commonly used “non-AF” PIMs were 
benzodiazepines (long, short and intermediate 
acting) (19.1%), followed by spironolactone (9.3%) 
and tricyclic antidepressants (TCA) (amitriptyline, 
imipramine) (7.6%). 
 
Table 3. Pharmacotherapy use and potentially inappropriate medicines (PIM): Cardiovascular agents. 
Main therapeutic classes and most 
common subclasses
 † 
N (%) of patients 
367 (100) 
Overall 






















Blood and blood forming agents (B) 361 (98.4) 19 (5.2) 140 (38.1) 202 (55.0) <0.01 
Antithrombotic agents (B01) 361 (98.4) 19 (5.24) 140 (38.1) 202 (55.0) <0.01 
Vitamin K antagonists (B01AA) 293 (79.8) 14 (3.8) 122 (33.3) 157 (42.8) <0.01 
Direct thrombin inhibitors (dabigatran) 
(B01AE) 
43 (11.7) 3 (0.8) 12 (3.3) 28 (7.6) <0.01 
Platelet aggregation inhibitors (B01AC) 38 (10.4) 2 (0.6) 7 (1.7) 29 (7.9) <0.01 
Cardiovascular system (C) 363 (98.9) 17 (4.6) 142 (38.7) 204 (55.6) 0.01 
Lipid modifying agents (C10) 228 (62.1) 10 (2.7) 85 (23.2) 133 (36.2) 0.42 
HMG CoA reductase inhibitors (C10AA) 220 (59.9) 9 (2.5) 84 (22.9) 127 (34.1) 0.42 
Antihypertensive agents (C02)      
Prazosin
‡ 
 (C02CA01) 19 (5.2) 1 (0.3) 9 (2.5) 9 (2.5) 0.73 
Methyldopa 
‡ 
 (C02AB) 6 (1.6) 0 (0.0) 1 (0.3) 5 (1.4) 0.31 











ACE inhibitors, plain (C09AA) 144 (39.2) 1 (0.3) 53 (14.4) 90 (24.5) <0.01 
Angiotensin II antagonists (C09CA) 119 (32.4) 4 (1.1) 47 (12.8) 68 (18.5) 0.56 
Calcium channel blockers (C08) 95 (25.9) 5 (1.4) 30 (8.2) 60 (16.3) 0.03 
Dihydropyridine derivatives (C08CA) 67 (18.3) 2 (0.6) 17 (4.6) 48 (13.1) 0.02 
Benzothiazepine derivatives (diltazem) 
(C08DB) 
17 (4.6) 0 (0.0) 7 (1.9) 10 (2.7) 1.00 
Phenylalkylamine derivatives (verapamil) 
(C08DA) 
21 (5.7) 3 (0.8) 6 (1.6) 12 (3.7) 0.12 
Diuretics (C03) 162 (44.1) 3 (0.8) 53 (14.4) 106 (28.8) <0.01 
Sulfonamides (C03CA) 140 (38.1) 3 (0.8) 43 (11.7) 94 (25.6) <0.01 
Aldosterone antagonists (spironolactone) 
(C03DA) 
34 (9.3) 0 (0.0) 11 (3.0) 23 (33.5) 0.22 
Beta Blocker agents (C07) 218 (59.4) 8 (2.2) 87 (23.7) 123 (3.5) 0.28 
Beta blocking agents, non-selective 
(C07AA) 
55 (14.9) 2 (0.6) 26 (7.1) 27 (7.3) 0.40 
Sotalol (C07AA07) 30 (9.8) 1 (0.3) 19 (5.2) 16 (4.4) 0.18 
Beta blocking agents, selective (C07AB) 154 (41.9) 10 (2.7) 51 (13.9) 93 (25.4) 0.12 
Cardiac therapy (C01) 175 (47.7) 10 (2.7) 71 (19.3) 94 (25.6) 0.74 















 (C01AA) 111 (30.2) 8 (2.2) 30 (8.2) 73 (19.9) <.0.01 
Flecainide 
‡  
(C01BC04) 8 (2.2) 1 (0.3) 3 (0.8) 4 (1.1) 0.67 
Organic nitrates (C01DA) 71 (19,3) 1 (0.3) 17 (4.6) 53 (14.4) <0.01 
NSAID: nonsteroidal anti-inflammatory drugs; TCA: tricyclic antidepressants; SSRI: selective serotonin reuptake inhibitors  
* Difference between non-polypharmacy, minor-polypharmacy and major-polypharmacy.  
†All medications were classified according to Anatomical Therapeutic Chemical (ATC) classification system. 
‡ Potentially inappropriate medicines (PIMs) according to both Beers criteria and PRISCUS criteria 
§ Within these 111 patients, 22 patients met Beers criteria for potentially inappropriate use of digoxin (i.e. digoxin 
>0.125mg/d). 
¶ Only included in Beers criteria. 
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DISCUSSION 
Our study presents some initial findings on the use 
of high-risk medications and polypharmacy, 
including PIMs, among older AF patients in a 
primary care setting. The study has identified a high 
prevalence of polypharmacy in older patients with 
AF (94.8%). This rate of polypharmacy is higher 
than reported in a study of older patients (aged 70 
or older years, including AF and non-AF patients), 
treated in the general practice setting in Germany
25
 
and higher than in an Australian study of older 
patients (aged 70 years or older) admitted to 
general medical units in acute care hospitals.
10
 Not 
unexpectedly, the most frequently prescribed 
medications included cardiovascular agents, 
consistent with other studies
26
, followed by 
antithrombotics. The significance of this is that 
these commonly used medications not only 
contribute to the burden of polypharmacy in AF 
patients, but they are also regarded to be high risk 
medicines and, in some cases, PIMs. Since these 
are guideline-indicated therapies for AF patients
1
, 
this polypharmacy comprising PIMs creates a 
particularly high-risk situation for patients, further 
increasing the likelihood of adverse drug reactions 
and medication misadventure.
27
 Regarding the use 
of aspirin as a monotherapy, evidence-based 
clinical practice guidelines suggest that aspirin 
Table 4. Pharmacotherapy use and potentially inappropriate medicines (PIM): Non-cardiovascular agents & overall use. 
Main therapeutic classes and most 
common subclasses
 † 
N (%) of patients 
367 (100) 
Overall 























Drugs for acid related disorders (A02)        198 (53.9) 6 (1.6) 55 (14.9) 137 (37.3) <0.01 
Proton pump inhibitor (A02BC) 156 (42.5) 6 (1.6) 43 (11.7) 107 (29.2) <0.01 
Drugs for functional gastrointestinal disorders 
(A03) 
     
Metoclopramide
¶
 (A03FA01) 8 (2.2) 0 (0.0) 2 (0.6) 6 (1.6) <0.01 
Psycholeptics (N05) 73 (19.9) 1 (0.3) 17 (4.6) 55 (14.9) 0.01 
Benzodiazepine derivatives (N05CD)                          





















Psychoanaleptics (N06) 70 (19.1) 1 (0.3) 13 (3.5) 56 (15.2) <0.01 
Antidepressant (N06A) 68 (18.5) 1 (0.3) 12 (3.3) 55 (14.9) <0.01 
TCA (N06AA) (amitriptyline, imipramine) 28 (7.6) 1 (0.3) 4 (1.1) 23 (6.2) <0.01 
SSRI (N06AB) (fluoxetine) 
‡
 24 (6.5) 0 (0.0) 5 (1.6) 19 (5.2) 0.03 
Analgesics(N02) 207 (56.4) 5 (1.4) 59 (16.2) 143 (39.0) <0.01 












Corticosteroids, dermatological preparations 
(D07) 
93 (25.3) 5 (1.4) 26 (28.0) 62 (16.9) 0.04 
Corticosteroid for systemic use (H02) 27 (7.4) 0 (0.0) 5 (1.4) 22 (6.0) 0.02 
Drugs for obstructive airway diseases (R03) 89 (24.3) 5 (1.4) 20 (5.4) 64 (17.4) <0.01 
Selective beta-2-adrenoreceptor agonists 
(R03AC) 
51 (13.9) 4 (1.1) 8 (2.2) 39 (10.6) <0.01 
Corticosteroids inhaler (R03BA)  61 (16.6) 4 (1.1) 14 (3.8) 43 (11.8) 0.02 
Drugs used in Diabetes (A10) 62 (16.9) 4 (1.1) 14 (3.8) 44 (12.0) 0.02 
Insulin and analogues (A10A) 14 (3.8) 0 (0.0) 3 (0.8) 11 (3.0) 0.19 
Blood glucose lowering drugs excl. insulin 
(A10B) 
56 (15.3) 4 (1.1) 13 (3.5) 39 (10.6) 0.03 
Anti-inflammatory and anti-rheumatic products 
(M01) 
     













16 (4.3) 0 (0.0) 5 (1.4) 11 (3.0) 0.29 
Sex hormones and modulators of the genital 
system (G03) 
     
Estrogen with or without progestin
¶ 
 (G03CA) 23 (6.3) 1 (0.3) 4 (1.1) 18 (4.9) 0.59 
Urologicals (G04)      
Urological spasmolytic agents (G04BD) 
(oxybutynine, tolterodine, solifenacin) 
‡
 
9 (2.5) 1 (0.3) 1 (0.3) 7 (1.9) 0.16 
Use of potentially inappropriate medications (PIMs) 
Overall use of PIMs 250 (68.2) 12 (3.3) 79 (21.5) 159 (43.3) <0.001 
One PIM (mean age =77.9 years) 144 (40.3) 9 (2.5) 56 (15.3) 84 (22.9) - 
Two PIMs(mean age =76.4 years) 68 (18.5) 2 (0.5) 15 (4.1) 51 (13.9) - 
Three PIMs (mean age =77.0 years) 38 (7.6) 1 (0.3) 7 (1.9) 20 (5.4) - 
Four PIMs (mean age =75.8 years). 5 (1.4) 0 (0.0) 1 (0.3) 4 (1.1) - 
NSAID: nonsteroidal anti-inflammatory drugs; TCA: tricyclic antidepressants; SSRI: selective serotonin reuptake inhibitors  
* Difference between non-polypharmacy, minor-polypharmacy and major-polypharmacy.  
†All medications were classified according to Anatomical Therapeutic Chemical (ATC) classification system. 
‡ Potentially inappropriate medicines (PIMs) according to both Beers criteria and PRISCUS criteria 
§ Within these 111 patients, 22 patients met Beers criteria for potentially inappropriate use of digoxin (i.e. digoxin 
>0.125mg/d). 
¶ Only included in Beers criteria. 
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alone is insufficient to reduce stroke risk. In our 
study, since the stroke risk in this patient sample 
was at least intermediate (as per CHA2DS2VASc ), 
the observed use of aspirin monotherapy was 




It is important to note that among the most 
commonly used AF therapies in this study, several 
(i.e., antiarrhythmics) were identified as PIMs 
according to Beers criteria or the PRISCUS list. In 
particular, the use of digoxin was surprisingly high in 
this study population and consistent with other 
studies.
28,29
 Given that digoxin is no longer 
recommended as a mainstay therapy, being 
reserved for those AF patients who have congestive 
heart failure unresponsive to first-line therapies, this 
possible overuse in patients with AF raises 
concerns about the safety and necessity of its use.
28
 
Medication safety in AF patients is further 
compounded when patients require 
pharmacotherapy for other non-AF conditions. As 
also reported in earlier studies, a surprisingly high 
number of patients used analgesics, suggesting that 
in older patients with AF there is a high prevalence 
of pain conditions (e.g., arthritis).
30
 The concurrent 
use of analgesics with AF pharmacotherapy may 
lead to drug interactions and/or GI (gastrointestinal) 
adverse drug reactions which may increase the risk 
of bleeding, especially GI bleeding. Noting that the 
prevalence of NSAIDs use in our study was only 
4.3%, much lower than other studies of AF 
patients
33
 and the use of NSAIDs in combination 
with warfarin only 2.5%, the rate of such interactions 
might be relatively low. Nevertheless, the episodic 
nature of pain can complicate AF management, 
because pain is symptomatic and therefore patients 
may prioritise analgesic use over AF therapy.
34
 
However, this study found that the use of 
paracetamol in combination with warfarin is 
relatively common. As reported by other studies, the 
interaction between warfarin and paracetamol is 
often underestimated, but is important because it 
can potentiate the anticoagulant effect of warfarin 
and increase the rate of fatal bleeding 2.7 times 
(compared to warfarin use alone).
19,20
 The 
mechanism of this interaction is not fully understood 
but some studies support the hypothesis that 
paracetamol (or its metabolites) interact with certain 
enzymes responsible for the synthesis of vitamin K 
dependent coagulation factors (vitamin K-




Although proton pump inhibitors (PPIs) are 
commonly used medications, this study shows that 
the use of PPIs is higher than that in other studies 
of general older patients in nursing homes
35
 and 
those admitted to hospitals.
36
 The frequent use of 
PPIs for GI conditions in our study raises concerns 
that many AF patients may potentially suffer from 
drug-induced GI adverse drug reactions, since a 
number of AF pharmacotherapies (e.g., 
antiarrhythmics, antithrombotics) are reported to 
cause GI symptoms, including upper GI bleeding. 
Separate to GI adverse drug reactions, according to 
the approved product information, acid-
minimising/suppressing agents (e.g., omeprazole)
37
 
may also interact with prescribed AF medications 
(e.g., warfarin, digoxin), increasing the potential for 




In relation to the over-use of therapies, a 
surprisingly high proportion of patients were found 
to be taking benzodiazepines in this study, which 
are recognised as a major cause of adverse drug 
reactions in the older patients.
39
 A previous study 
pertaining to general older patients (aged >65 
years) in the Australian general practice setting 
reported that 45% of patients using 
benzodiazepines experienced two to six adverse 
drug reactions, whilst 15% of patients had seven or 
more reactions during the study period.
39
 
Benzodiazepines, as well as other psycholeptics, 
psychoanaleptics, diuretics, antihypertensive 
agents, anti-inflammatory and anti-rheumatic 
products (e.g., NSAIDs) are regarded as PIMs in 
older persons; many of these may lead to a high 
risk of falls, and/or increased risk of intracranial 
bleeding, whilst others can cause GI bleeding, 




Regarding the different classifications of bleeding 
risk assessment, two tools were used: HAS-BLED, 
which is widely incorporated into international 
treatment guidelines
1,2
, and HEMORR2HAGES, as 
recommended by National Clinical Guideline Centre 
(UK) and American College of Cardiology/American 
Heart Association guidelines.
1,19
 Compared with 
HAS-BLED, HEMORR2HAGES uniquely includes a 
wider range of risk factors namely: malignancy, 
anemia, genetic factors, reduced platelet count or 
function, excessive falls risk, in addition to the 
common bleeding risk factors (e.g., hypertension, 
abnormal renal/liver function, stroke, bleeding 
predisposition, age, alcohol use). HAS-BLED has 
better sensitivity than HEMORR2HAGES in 
identifying any clinically relevant bleeding in 
anticoagulated patients with AF.
41
 However, 
HEMORR2HAGES has a higher diagnostic 
accuracy due to its higher specificity.
41
 The 
Table 5. Antithrombotic therapy use stratified according to stroke risk 
Stroke risk N 















       
Low 25 (6.8) 1 (0.3) 2 (0.5) 0 (0.0) 1 (0.3) 0 (0.0) 
Intermediate 87 (23.7) 1 (0.3) 14 (3.8) 0 (0.0) 7 (1.9) 1 (0.3) 
High 167 (45.5) 12 (3.3) 27 (7.4) 3 (0.8) 14 (3.8) 5 (1.4) 
CHA2DS2-VASc score
§
       
Intermediate 11 (3.0) 1 (0.3) 1 (0.3) 0 (0.0) 1 (0.3) 0 (0.00 





  scores of 0, 1, 2 or more were classified as low, intermediate and high stroke risk, 
respectively. 
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association between a lower HEMORR2HAGES 
(but not HAS-BLED) score and polypharmacy may 
be explained by the wider range of risk factors 
included in it, although none of the individual risk 
factors were found to be significantly associated 
with polypharmacy in this study. In this regard, 
decision support tools (such as CARAT
42
) can help 
assess these risk factors when recommending 
antithrombotic therapy, and therefore maybe useful 
in identifying the potential for polypharmacy (and 
therefore any medication safety issues). 
This study has identified that patients using 
polypharmacy are also more likely to have a low risk 
of bleeding. Given that the decision-making around 
the use of antithrombotics in AF focuses on 
weighing the risk of stroke versus the risk of 
bleeding, in this equation these “low risk” patients 
(low bleeding risk) are generally deemed to be more 
eligible for anticoagulants (e.g., warfarin) than 
patients at a higher bleeding risk. However, these 
same low-risk patients are also more likely to have 
polypharmacy (as identified here), thereby 
increasing the risk of drug-drug interactions, 
adverse drug reactions and treatment non-
adherence. Therefore, in prescribing 
antithrombotics for AF patients, clinicians must 
consider both the stroke versus bleeding risks 
alongside the relevant medication safety 
considerations (i.e., the implications of 
polypharmacy), to ensure that in optimising 
antithrombotic therapy they are not inadvertently 
putting “low risk” patients at high risk of medication 
misadventure. Whilst this should not stop the use of 
antithrombotics, it does reinforce the need for 
comprehensive patient assessment with regular 
review and follow-up to monitor for medication 
misadventure in all patients including those 
apparently at “low risk”. 
In this study, patients with major-polypharmacy 
were more likely to have obstructive pulmonary 
disease (asthma or COPD), upper gastrointestinal 
disease and poor physical function (as per SF-36), 
but less likely to have cognitive impairment. This is 
consistent with other studies showing that asthma 
or COPD and gastrointestinal disease
43,44
 are 
associated with excessive polypharmacy (≥10 
drugs).
45
 Possible reasons include that obstructive 
pulmonary disease can cause a range of different 
comorbidities, including heart disease (e.g., heart 
failure, arrhythmias), chronic kidney disease, 
cancer, metabolic disease (e.g., osteoporosis, 
diabetes) and pulmonary embolism.
46
 Since patients 
with upper gastrointestinal disease have a higher 
risk of gastrointestinal bleeding
38
, the association of 
upper gastrointestinal diseases with major-
polypharmacy in patients with AF needs some 
vigilance; the concomitant use of oral 
antithrombotics (e.g., dabigatran, aspirin) and 
NSAIDs in the presence of polypharmacy and 
gastrointestinal disease may predispose patients to 
an increased risk of GI haemorrhage and 
associated morbidity and mortality. Similarly, poor 
physical function (measured by SF-36), as reported 
by previous studies was found to be associated with 
the use of an increased number of medications.
47
 
Since patients with polypharmacy are at higher risk 
of adverse reactions
5
, it is important to balance the 
need for multiple medications with patients’ desired 
quality of life. In contrast, cognitive impairment has 
been shown to be associated with a reduced use of 
medications.
43,44
 This may be due to prescribers’ 
concerns about using multiple medications in those 
patients, as studies have shown that cognitive 
impairment may cause lower adherence and 
communication difficulties, including a decreased 
ability to report adverse effects.
48,49
  
The ‘trilogy’ of risks in older AF patients warrants 
specific attention when managing their medication 
regimens. Services such as Home Medicines 
Review (HMR)
50
 can help to assess the medication 
regimens of such patients, and have been shown to 
reduce the use of PIMs.
51
 Other services such as 
MedsCheck (medicines use review) and Diabetes 
MedsCheck (diabetes medication management) are 
structured pharmacy services, involving face-to-face 
consultations between the pharmacist and 
consumer.
52
 These services are designed to 
enhance the quality use of medicines through 
patient education, self-management and medication 
adherence strategies, and may help to reduce the 
medication misadventure experienced by patients.
53
 





, can assist in 
quantifying the stroke or bleeding risk for an 
individual patient. However, medication 
management in AF patients requires a more careful 
balance of risks and benefits to ensure optimal 
therapy that not only minimises the stroke and 
bleeding risks, but also reduces the risk for 
medication misadventure from any cause.  
Targeted decision support tools, which 
systematically assess a patient’s medical history, 
stroke and bleeding risk and which consider 
pertinent medication safety issues (e.g. 
polypharmacy, drug-drug interactions), may assist 
here
42
; these tools can support prescribing as well 
as facilitate the regular review of medication 
regimens. Regular medication review services using 
risk assessment tools may help reduce the risk and 
optimise medication use. However, there are still 
some gaps in implementing these tools and 
services in the medication management of AF 
patients. Designed for specific contexts (e.g., 
stroke, bleeding) or certain types of medication 








alone may not be completely useful in the 
comprehensive review and management of AF 
patients’ overall medication regimen (as opposed to 
just their antithrombotic therapy). Also, these tools 
and services have not yet been evaluated in large-
scale studies involving older AF patients. Therefore, 
given that the use of pharmacotherapy in this 
specific context (older persons with AF) is complex, 
further research needs to more comprehensively 
investigate the risk factors and explore the impact of 
targeted interventions on managing the ‘trilogy’ of 
risks.  
In considering the findings of this study, some 
limitations need to be acknowledged. The 
retrospective nature of the study, and the limited 
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number of AF patients in the cohort reviewed, result 
in relatively wide confidence intervals, requiring that 
the findings to be interpreted with caution. The 
logistic regression analysis for the outcome “major-
polypharmacy versus minor polypharmacy” has 
limited prediction value, which means that there 
may be other risk factors associated with major-
polypharmacy which need to be explored in future 
studies. However, the selection of these patients is 
representative of older patients with AF 
encountered in the Australian general practice 
setting, providing an important insight into the 
specific challenges of using pharmacotherapy in this 
patient cohort. Furthermore, although there is 
uncertainty around the reliability of GPs’ medication 
records as the primary source of medication 
histories, the medication lists recorded in this study 
were verified by the GPs. Due to the cross-sectional 
design of this study, only explicit criteria were used 
to identify PIMs. Though many of the results of this 
study confirm the previous findings in the literature, 
this study is first to demonstrate the relationship 
between low-bleeding risk and polypharmacy.  
 
CONCLUSIONS 
Polypharmacy affects most older AF patients, 
comprising medications that are indicated for AF, 
yet regarded as PIMs. Patients with a lower risk of 
bleeding, obstructive pulmonary disease, upper 
gastrointestinal disease and poor physical function 
are significantly more likely to use multiple 
medications. This may lead to an increased risk of 
medication misadventure due to the concomitant 
use of polypharmacy and high-risk medications 
indicated for AF. 
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